Purespring Therapeutics Secures £80 Million for Kidney Treatments
Purespring Therapeutics, a groundbreaking gene therapy company specializing in kidney diseases, has recently announced a significant funding achievement, raising £80 million in a Series B financing round. This substantial investment was led by Sofinnova Partners and supported by a collaboration of esteemed investors including Gilde Healthcare, Forbion, British Patient Capital, and founding investor Syncona Limited.
The funds secured will primarily facilitate Purespring's advancement of its AAV gene therapy programs, significantly benefiting the treatment of various kidney conditions, notably IgA Nephropathy (IgAN), which is a common chronic kidney disease.
Purespring's Unique Approach to Kidney Disease
At the forefront of innovation, Purespring is the pioneer in directly targeting podocytes—specialized cells that play a crucial role in kidney function and are implicated in approximately 60% of renal diseases. Through its proprietary adeno-associated viral (AAV) gene therapy platform, the company is making strides in developing effective therapies for kidney diseases.
Currently, Purespring has a robust pipeline in development, which includes not only its lead program aimed at IgAN but also initiatives targeting nephrotic syndrome and other complement-mediated kidney diseases. This strategic focus on podocyte intervention marks a vital advancement in the treatment landscape for renal diseases, addressing a significant unmet clinical need.
Funding Utilization and Clinical Trials
The financial influx from this Series B round will be pivotal in pushing Purespring’s programs forward, especially the initiation of a Phase I/II clinical trial for IgAN. This particular kidney disease predominantly affects younger adults, and unfortunately, a third of those diagnosed can lose kidney function within five years, increasing their likelihood of needing transplant or dialysis treatments.
Leadership Perspectives and Vision
Julian Hanak, the CEO of Purespring, expressed, “Nearly one-tenth of the world’s population suffers from chronic kidney disease. Many of these individuals have few options available other than dialysis and transplantation. Our innovative treatment platform positions us uniquely to halt, reverse, and potentially cure kidney disease.”
Hanak emphasized the importance of the support from a dedicated investor syndicate, which will amplify Purespring's efforts in getting these critical therapies to patients who urgently need them.
Expert Endorsements
Maina Bhaman from Sofinnova Partners remarked on Purespring’s ambitious journey, highlighting the company's commitment to transformative kidney disease treatments. Similarly, Michael Kyriakides, from Syncona Investment Management, noted the impressive progress Purespring has made since its inception and commended the financing round as a testament to the company's validated technology and strategy.
Milestones and Future Directions
Purespring's financing journey is following a series of significant scientific milestones. Earlier this year, the company showcased preclinical data establishing the effectiveness of AAV gene therapy in delivering therapeutic transgenes to podocytes, a breakthrough in the field.
As part of its commitment to transparency and scientific advancement, Purespring is set to present its IgAN data for the first time at an upcoming congress, positioning itself as a notable player in the international kidney health landscape.
About Purespring Therapeutics
Founded on the pioneering work of Professor Moin Saleem, Purespring is dedicated to creating gene therapies aimed at halting and preventing kidney disease—a field that has traditionally been plagued by treatment challenges. By focusing on genetic diseases, including those caused by mutations in key kidney-related genes, Purespring aims to reshape the treatment paradigm for both rare and common kidney diseases.
The team's extensive experience in podocyte biology, combined with their commitment to innovation and research, positions Purespring uniquely within the biotechnology sector. With the support of leading investors, the company has successfully raised a total of £115 million to date, bolstering its mission to deliver transformative treatments to patients in need.
Frequently Asked Questions
What is the goal of Purespring Therapeutics?
Purespring aims to develop innovative gene therapies to revolutionize the treatment of kidney diseases.
How much funding did Purespring raise?
Purespring raised £80 million in its latest Series B financing round.
Who were the leading investors in this financing?
The round was led by Sofinnova Partners, along with Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
What specific kidney disease treatments is Purespring developing?
Purespring is developing treatments targeting IgA Nephropathy, nephrotic syndrome, and various complement-mediated kidney diseases.
What is the significance of the AAV gene therapy platform?
The AAV platform allows for specific and efficient delivery of therapeutic genes to renal podocytes, potentially transforming treatments for kidney diseases.
